A pancreas tumor derived organoid study: from drug screen to precision medicine.

Yao, Jia; Yang, Man; Atteh, Lawrence; Liu, Pinyan; Mao, Yongcui; Meng, Wenbo; Li, Xun

Yao, Jia; Yang, Man; Atteh, Lawrence; Liu, Pinyan; Mao, Yongcui; Meng, Wenbo; Li, Xun.

Afiliación

Yao J; Key Laboratory of Biological Therapy and Regenerative Medicine Transformation of Gansu Province, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.
Yang M; The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu, China.
Atteh L; The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu, China.
Liu P; The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu, China.
Mao Y; The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu, China.
Meng W; Department of General Surgery, The First Hospital of Lanzhou University, The First Clinical Medical School of Lanzhou University, Lanzhou, 730000, Gansu, China. mengwb@lzu.edu.cn.
Li X; Department of General Surgery, The First Hospital of Lanzhou University, The First Clinical Medical School of Lanzhou University, Lanzhou, 730000, Gansu, China.

Cancer Cell Int ; 21(1): 398, 2021 Jul 27.

Article en En | MEDLINE | ID: mdl-34315500

Palabras clave

Drug screen; Pancreas cancer; Pancreas tumor derived organoids (PTOs); Pancreatic ductal adenocarcinoma (PDAC); Precision medicine

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: Cancer Cell Int Año: 2021 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google